Invention Grant
- Patent Title: Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptors
-
Application No.: US16821674Application Date: 2020-03-17
-
Publication No.: US11702472B2Publication Date: 2023-07-18
- Inventor: Prasad S. Adusumilli , Michel Sadelain , Dimiter S. Dimitrov , Yang Feng
- Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER , The U.S.A. as Represented by the Secretary, Department of Health and Human Services
- Applicant Address: US NY New York
- Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER,THE U.S.A. AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
- Current Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER,THE U.S.A. AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
- Current Assignee Address: US NY New York; US MD Bethesda
- Agency: Baker Botts L.L.P.
- The original application number of the division: US15368278 2016.12.02
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K14/725 ; C07K16/30 ; C07K14/705 ; C07K14/47 ; A61K39/00 ; A61K38/00 ; A61K35/00
Abstract:
The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
Public/Granted literature
- US20200239569A1 USES OF MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS Public/Granted day:2020-07-30
Information query
